CBL and acute lymphoblastic leukemia: CBL is rarely mutated in BCP ALL, but identifying cases with CBL mutations may be clinically relevant because they have been shown to be associated with constitutive activation of the RAS pathway and to be sensitive to MEK inhibitors [8].